Marshall Wace LLP raised its position in Sema4 Holdings Corp. (NASDAQ:SMFR – Get Rating) by 14.9% in the 3rd quarter, Holdings Channel reports. The fund owned 5,650,286 shares of the company’s stock after acquiring an additional 734,605 shares during the period. Marshall Wace LLP’s holdings in Sema4 were worth $4,973,000 as of its most recent filing with the SEC.
Several other hedge funds also recently made changes to their positions in the company. Bank of New York Mellon Corp lifted its stake in shares of Sema4 by 21.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 852,498 shares of the company’s stock worth $748,000 after acquiring an additional 149,799 shares during the period. BlackRock Inc. lifted its stake in shares of Sema4 by 5.5% in the 3rd quarter. BlackRock Inc. now owns 13,432,597 shares of the company’s stock worth $11,786,000 after acquiring an additional 703,049 shares during the period. Oracle Investment Management Inc. lifted its stake in shares of Sema4 by 27.6% in the 3rd quarter. Oracle Investment Management Inc. now owns 8,403,926 shares of the company’s stock worth $7,374,000 after acquiring an additional 1,818,572 shares during the period. SG Americas Securities LLC lifted its stake in shares of Sema4 by 50.7% in the 3rd quarter. SG Americas Securities LLC now owns 99,986 shares of the company’s stock worth $88,000 after acquiring an additional 33,643 shares during the period. Finally, Zweig DiMenna Associates LLC lifted its stake in shares of Sema4 by 4.3% in the 3rd quarter. Zweig DiMenna Associates LLC now owns 1,339,883 shares of the company’s stock worth $1,176,000 after acquiring an additional 55,000 shares during the period. Institutional investors and hedge funds own 56.01% of the company’s stock.
Sema4 Stock Up 6.1 %
SMFR opened at $0.36 on Tuesday. The company has a market capitalization of $137.32 million, a P/E ratio of -0.39 and a beta of 1.61. The firm’s fifty day moving average price is $0.42 and its two-hundred day moving average price is $0.63. Sema4 Holdings Corp. has a fifty-two week low of $0.22 and a fifty-two week high of $4.67. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.89 and a quick ratio of 1.62.
Analyst Upgrades and Downgrades
Sema4 Company Profile
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services.
- Get a free copy of the StockNews.com research report on Sema4 (SMFR)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Want to see what other hedge funds are holding SMFR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sema4 Holdings Corp. (NASDAQ:SMFR – Get Rating).
Receive News & Ratings for Sema4 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sema4 and related companies with MarketBeat.com's FREE daily email newsletter.